| Literature DB >> 8351023 |
J Rogers1, L C Kirby, S R Hempelman, D L Berry, P L McGeer, A W Kaszniak, J Zalinski, M Cofield, L Mansukhani, P Willson.
Abstract
In a 6-month, double-blind, placebo-controlled study, 100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer's disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (+/- 1.8%), whereas placebo patients declined 8.4% (+/- 2.3%)--a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.Entities:
Mesh：
Substances：
Year: 1993 PMID： 8351023 DOI： 10.1212/wnl.43.8.1609
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910